QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Organogenesis Holdings Inc. (ORGO)

Healthcare

No action
Fundamental
1
Sentiment
2
Technical
1

Do Nothing: fundamentalScore 1 and qualitativeScore 2 are both below the required floor of 3 (independent hard overrides, and the shadow sum-gate branch is unavailable because the shadow flag rendered false), and the name also fails both liquidity tests — avgDollarVolume20 ~$1.07M versus the $5M floor and recent 3-session regular-session dollar volume ~$0.83M versus the $1.5M floor; the chart is a broken downtrend (price under every MA, ADX 46 with price falling) and neither a pullback limit (countertrend: price < sma50 with macdLine < 0, and under a declining sma200 without a reclaim) nor a breakout stop (nearest settled level 1.06 → R/R 0.69) qualifies.

Analysis as of 2026-11-14· more than 2 trading days ago

Company overview

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine company specializing in advanced wound management, surgical, and sports medicine therapies. Its product portfolio includes bioengineered solutions like Apligraf and Dermagraft, as well as amniotic membrane dressings such as Affinity and Novachor.

Fundamental

very weak
Fundamental1
Speculative fundamentals

Organogenesis faces a significant revenue decline due to Medicare reimbursement changes, with speculative and deeply impaired fundamentals.

Revenue is collapsing under the 2026 Medicare skin-substitute payment reset (−69.8% in Q3 2026), the company is burning cash with no committed credit facility, and a $150.9M preferred sits ahead of the common stock; the only offsets are positive working capital, no funded debt and aggressive cost cuts. Fundamentals read speculative and deeply impaired.

Sentiment

weak
Sentiment2
Bearish sentiment

Sentiment is bearish with no positive catalysts, and recent earnings have been poorly received.

The dominant short-term driver is the announced Q3-2026 earnings print (2026-11-05): net revenue of $45.5M versus $150.5M a year earlier, roughly a 70% decline, a $29.6M net loss against prior-year net income, a 73% drop in Advanced Wound Care tied to the LCD coverage-policy withdrawal, and a 13.43% single-session stock decline — the tape read it as a miss on both revenue and EPS, so direction is set from reception rather than from the release framing. Sentiment delta is indeterminate because the 30–90d baseline returned no usable directional content (2 scored items, both 0.0, one an extraction-failed page), which leaves a uniformly bearish 14-day scoring window (polarity_score ≈ −0.31, zero positive items), no forward-dated catalyst inside 30 days, and no offsetting bullish leg, while the Red-Flag Screen is not clean because the moderate deteriorating-sentiment-with-no-offsetting-bullish-catalyst flag fired and a moderate red-flag cap applies.

Technical

very weak
Technical1
Strong downtrend

The stock is in a strong downtrend, with price below all moving averages and high ADX confirming the downward move.

Bearish / broken structure (score 1). Price 0.8101 sits below every reference average — sma20 0.90, ema9 0.90, wma9 0.91, dema14 0.86, tema14 0.90, ema21 0.96, sma50 1.19 and sma200 2.22 — with sma50 < sma200, i.e. a fully stacked declining MA structure. ADX14 46.06 is high, and read together with price under all MAs it confirms a strong DOWNtrend, not bullish trend strength. RSI14 37.31 and Williams %R -75.73 are weak but not oversold; MACD line -0.09 remains below signal -0.11 (histogram only +0.03), i.e. momentum is still negative and only mildly narrowing. The 2026-11-02 → 2026-11-11 bounce (0.7555 → 1.05, +39%) fully failed: -8.1% on 11-12 and -13.74% on 11-13 returned price to 0.8101, just above the 0.73 52-week low. Volume skews to distribution (down days 1.22M and 0.69M shares against a 0.89M up day). There is no tradable bullish setup, and the trade is independently blocked upstream by fundamentalScore 1 and qualitativeScore 2 and by both liquidity floors.

You’re looking at 2026-11-14 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.